| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3718 | Nr2b-in-1 | Novel NMDA/NR2B Antagonist |
|
| DCC3719 | Nrf2/ho-1 Activator Ll202 | Novel activator of the Nrf2/HO-1 pathway, upregulating heme oxygenase-1 (HO-1) via promoting nuclear translocation of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) to regulate LPS‐induced oxidative stress in macrophages |
|
| DCC3720 | Nrf2-activator Featured | Nrf2-Activator is a potent Nrf-2 activator. |
|
| DCC3721 | Ns-0011 | Novel inhibitor of CDK5 translocation, increasing CDK5 accumulation in the nucleus, suppressing both cancer cell proliferation and xenograft tumorigenesis. |
|
| DCC3722 | Ns-2710 | Potent, non-selective partial agonist at GABAA receptors with little efficacy at the alpha1 subtype and more at alpha2 and alpha3 |
|
| DCC3723 | ns3/4a-in-12 | Novel Inhibitor with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes |
|
| DCC3724 | ns3-in-5 | Novel allosteric inhibitor of HCV NS3 protein function |
|
| DCC3725 | Ns4591 | Novel molulator of SK-IK channels [small- and intermediate-conductance Ca2(+) -activated K(+) channels] |
|
| DCC3726 | Ns-6740 | Novel potent α7 nAChR partial agonist |
|
| DCC3727 | Ns-6784 Hydrochloride | Novel α7 nAChR agonist at human and rat receptors |
|
| DCC3728 | Nsc10010 | Novel potent growth inhibitor for gammaherpesvirus-associated B-lymphomas through activation of both the NF-κB and c-Myc-mediated signaling pathways |
|
| DCC3729 | Nsc1008 | Novel Inhibitor of the Ras Converting Enzyme 1 (Rce1) Protease, Disrupting Ras Membrane Localization in Human Cells |
|
| DCC3730 | Nsc-100874 | Novel antagonist of the Grb7 SH2 domain; Antitumor Agent |
|
| DCC3731 | Nsc1011 | Ras converting enzyme 1 (Rce1) inhibitor |
|
| DCC3732 | Nsc103054 | Novel inhibitor of ABCG2 transporter function |
|
| DCC3733 | Nsc-104999 | Ligand of the Grb7 SH2 domain, inhibiting the growth of MDA-MB-468 cancer cells |
|
| DCC3734 | Nsc107392 | Novel substrate of ABCG2 |
|
| DCC3735 | Nsc109131 | Inhibitor of human tyrosyl-DNA phosphodiesterase 1 (TDP1) |
|
| DCC3736 | Nsc109779 | Novel potent inhibitor of Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein |
|
| DCC3737 | Nsc114792 | Novel selective inhibitor of JAK3 |
|
| DCC3738 | Nsc-117199 | Selective inhibitor of shp2 protein tyrosine phosphatase (PTP) |
|
| DCC3739 | Nsc-12404 | Selective non-lipid agonist of LPA2/3 |
|
| DCC3740 | Nsc-126188 | Apoptosis inducer; Antitumor agent |
|
| DCC3741 | Nsc127133 | Novel inhibitor of the second bromodomain (BD2) of the BET family protein BRD2 |
|
| DCC3742 | Nsc-13030 | Novel potent SHP2 Inhibitor with Anti-Proliferative Activity in Breast Cancer Cell Lines |
|
| DCC3743 | Nsc-134754 | HIF-pathway inhibitor |
|
| DCC3744 | Nsc13987 | Novel inhibitor of Nef-calnexin interaction |
|
| DCC3745 | Nsc-140873 | Inhibitor of the RUNX1-CBFβ interaction |
|
| DCC3746 | Nsc16168 | Specific inhibitor of ERCC1-XPF with no effect on both HhaI and XPG |
|
| DCC3747 | Nsc175176 | Novel potent and selective serotonin reuptake inhibitor (SSRI) |
|
